Almecillin

Last updated
Almecillin
Penicillin O.svg
Clinical data
Other names[(Allylthio)methyl]penicillin
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C13H16N2O4S2
Molar mass 328.40 g·mol−1
3D model (JSmol)
  • CC1(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N2[C@H]1C(=O)O
  • InChI=1S/C13H18N2O4S2/c1-4-5-20-6-7(16)14-8-10(17)15-9(12(18)19)13(2,3)21-11(8)15/h4,8-9,11H,1,5-6H2,2-3H3,(H,14,16)(H,18,19)/t8-,9+,11-/m1/s1
  • Key:QULKGELYPOJSLP-WCABBAIRSA-N

Almecillin (INN), [1] also known as penicillin O, is a penicillin that is similar in antibiotic action to penicillin G. It is obtained by isolation from Penicillium chrysogenum . [2]

Related Research Articles

An international nonproprietary name (INN) is an official generic and non-proprietary name given to a pharmaceutical drug or an active ingredient. INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since 1953.

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

Mitiglinide

Mitiglinide is a drug for the treatment of type 2 diabetes.

Omapatrilat

Omapatrilat is an experimental antihypertensive agent that was never marketed. It inhibits both neprilysin and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.

Arfendazam Chemical compound

Arfendazam (INN) is a drug which is a benzodiazepine derivative. Arfendazam is a 1,5-benzodiazepine, with the nitrogen atoms located at positions 1 and 5 of the diazepine ring, and so is most closely related to other 1,5-benzodiazepines such as clobazam.

Metampicillin

Metampicillin (INN) is a penicillin antibiotic. It is prepared by the reaction of ampicillin with formaldehyde, and is hydrolysed in aqueous solution with the formation of ampicillin. Hydrolysis is rapid under acid conditions, e.g., in the stomach, less rapid in neutral media, and incomplete in solutions such as human serum.

Bradanicline Chemical compound

Bradanicline is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials..

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are the International Nonproprietary Names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.

Tofogliflozin

Tofogliflozin is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. As of September 2012, the drug is in Phase III clinical trials.

Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC

Lulizumab pegol is a monoclonal antibody designed for the treatment of autoimmune diseases.

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.

Seribantumab is a monoclonal antibody designed for the treatment of cancer.

Plozalizumab is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.

Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

Mirikizumab is a human monoclonal antibody designed for the treatment of psoriasis.

Flotetuzumab is a bispecific antibody designed for the treatment of acute myeloid leukemia.

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 40" (PDF). World Health Organization. p. 170.
  2. ↑ "Penicillin O". ChEBI. EMBL-EBI. Retrieved 11 June 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.